Washington: US President Donald Trump's plan to overhaul childhood vaccinations could create major financial and logistical challenges for parents, healthcare providers and drugmakers, public health experts and industry specialists have warned.

An executive order announced on Monday calls for combination vaccines, including the measles, mumps and rubella (MMR) vaccine, to be separated into individual injections. It also calls for vaccination appointments to be spaced out whenever possible.

Implementing the plan would require drugmakers to revive individual vaccines that have not been widely used in the US for decades. Manufacturers could also need to build new facilities capable of producing millions of additional vaccine doses.

For parents, separating the MMR vaccine and spacing out other vaccinations could mean substantially more visits to doctors. The change could also place additional pressure on paediatricians and increase costs associated with syringes and other medical supplies.

Studies in the US and other countries have found that combination vaccines increase the likelihood that children will be fully protected against infectious diseases before starting school.

Health experts have said there is no scientific basis for changing the current approach.

“We do things that are less convenient and more expensive if there's a good reason to do it,” said Dr Anna Durbin of the Johns Hopkins Bloomberg School of Public Health. “There is no good justification for this. I think it's very bad public health policy.”

Trump’s plan would require vaccine manufacturing overhaul

Under the executive order, federal officials have been instructed to develop plans within 90 days for separating the MMR vaccine and spacing out other vaccinations.

Pharmaceutical scientists and former regulators said such changes could take years and require drugmakers to spend tens of millions of dollars on new studies and manufacturing facilities.

There are currently no individual measles, mumps or rubella vaccines in the US. Vaccines approved by the Food and Drug Administration for those viruses are combination shots, with the three-in-one MMR vaccine having been the standard in the US since the 1970s.

Dr Jesse Goodman, a former FDA vaccine chief, said manufacturers may have to conduct large studies to demonstrate that individual vaccines produce immune responses in children comparable to those generated by existing combination vaccines.

The requirements would depend on the quality of data available from the original standalone vaccines and how FDA regulators assess that evidence, Goodman said. He is now a professor at Georgetown University.

“The question is how much has changed since then and how comfortable will the FDA and the companies be relying on those comparisons?” Goodman said.

Manufacturers may also have to demonstrate the safety of new facilities and production procedures, given that individual measles vaccines have not been widely produced in the US for decades.

Designing, constructing and obtaining federal approval for new vaccine plants typically takes about five years, according to industry experts.

Goodman also said the FDA would have to review and license each unbundled vaccine separately, a process he described as having no precedent.

“I don't think there's any comparable example of removing hugely effective public health measures that protect babies for no documented scientific reason,” he said.

Individual vaccines for measles and related diseases are more commonly used in lower-income countries where combination vaccines may be less affordable. Merck, GSK and other companies that supply childhood vaccines in the US currently produce the combination MMR vaccine.

Merck and GSK said in separate statements that they stand by the safety and effectiveness of their products. Neither company discussed plans to separate the vaccines.

“To date, there has been no published scientific evidence that shows any benefit in separating the combination MMR vaccine into three individual shots,” Merck said in an emailed statement.

Parents could face more trips to the doctor

The MMR vaccine is currently administered in two doses, with the first given at around age one and the second after age four.

Separating the vaccine into three components could mean six separate office visits. Spacing out other vaccines against pertussis and other infectious diseases could increase the number of appointments even further.

As the number of visits rises, parents may be more likely to miss appointments or stop attending them altogether, Durbin said.

“It's going to be less convenient, more expensive and you're going to have fewer people getting vaccinated,” she said.

Trump has for more than a decade argued, against the guidance of medical organisations, that American children receive too many vaccines and that vaccinations should be administered in smaller doses over a longer period.

Last year, he called on Health Secretary Robert F Kennedy Jr to examine whether the number of childhood vaccinations could be reduced. Kennedy and other officials have pointed to countries such as Denmark, which recommends a somewhat different vaccination schedule from the US.

However, breaking up combination vaccines would result in children receiving more individual injections than children in comparable countries, Durbin said.

White House spokesman Kush Desai said the administration's efforts involving the MMR vaccine “will give parents more options on timing and frequency for their children, which ultimately will increase vaccination rates for all three diseases.”

Vaccine order may not compel drugmakers

Despite the unprecedented nature of the executive order, some experts remain sceptical about whether it will result in significant changes.

Neither the White House nor the FDA can compel pharmaceutical companies to develop and seek approval for new individual vaccines.

From a business perspective, manufacturers also have limited incentive to develop separate versions of vaccines that they already produce successfully as combination products.

The proposed changes could therefore face significant scientific, regulatory, manufacturing and practical obstacles before they can be implemented.